Clinical Trials ArenaOriginal article
HaemaLogiX doses first patient with KMCAR T-cell in KOALA trial
Phase 1KMCAR T-cellPositive
AI Analysis
Summary
HaemaLogiX dosed the first patient with KMCAR T-cell therapy in the Phase I KOALA trial for relapsed or refractory kappa-restricted multiple myeloma.
Clinical Trial Data
Phase
Phase I
Patients
1
Outcome Details
first patient dosed
Importance:3/10
Sentiment:
0.50
cell therapymultiple myelomaCAR-Ttrial initiation
Read the original article
Published by Clinical Trials Arena on August 27, 2026 8:50 AM